Here, through a comprehensive analysis of responders and non-responders to PD-1 treatment, along with myeloid and T-cell subpopulations in untreated patients, we identified previously unreported features of the TME in HCC patients (Figure 8J-K). This evidence concerns the gene PDCD1 and hepatocellular carcinoma.